MILLENIUM STILL FAVORED IN BID FOR ANORMED

It looks like Millennium Pharmaceuticals Inc. remains the favored bidder of a Canadian biotech, despite signs from Genzyme Corp. that it is poised to raise its bid. AnorMed Inc. of Vancouver, BC announced on Thursday that Cambridge, Mass.-based Genzyme has proposed raising its offer for the company from $8.55 per share to more than $12 per share, surpassing Millennium's $515 million bid.

Boston Business Journal (http://boston.bizjournals.com/boston/stories/2006/10/02/daily46.html)